Patents by Inventor Alexander Aronov

Alexander Aronov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF C21H22Cl2N4O2
    Publication number: 20220324832
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 13, 2022
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Crystalline forms of CHClNO
    Patent number: 11390600
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: July 19, 2022
    Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • CRYSTALLINE FORMS OF C21H22Cl2N4O2
    Publication number: 20200339531
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 29, 2020
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Crystalline forms of CHClNO
    Patent number: 10738027
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 11, 2020
    Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • CRYSTALLINE FORMS OF C21H22Cl2N4O2
    Publication number: 20190127348
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: December 20, 2018
    Publication date: May 2, 2019
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Crystalline forms of CHClNO
    Patent number: 10183927
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: January 22, 2019
    Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • CRYSTALLINE FORMS OF C21H22Cl2N4O2
    Publication number: 20170320851
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 9, 2017
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Crystalline forms of CHClNO
    Patent number: 9676746
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: June 13, 2017
    Assignees: BioMed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • CRYSTALLINE FORMS OF C21H22Cl2N4O2
    Publication number: 20160221987
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: January 29, 2016
    Publication date: August 4, 2016
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases
    Patent number: 8580802
    Abstract: The present invention relates to compounds of the following structural formula: which are useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: November 12, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Luc Farmer, Tiansheng Wang, Jian Wang, Randy Bethiel, Marion Wannamaker, Gabriel Martinez-Botella, John Duffy, Alexander Aronov, David Lauffer, Albert Pierce
  • Heterocyclic inhibitors of c-Met and uses thereof
    Patent number: 8481538
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: July 9, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Aronov, Jon Come, John Court, David Deininger, David Lauffer, Pan Li, Kira McGinty, Suganthini Nanthakumar, Dean Stamos, Kirk Tanner
  • c-MET protein kinase inhibitors
    Patent number: 8232406
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 31, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, Jr., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
    Publication number: 20110135603
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: October 15, 2010
    Publication date: June 9, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Tiansheng Wang, Alexander Aronov, Mark Cornebise, Francois Maltais, Mark Ledeboer, Arnaud Le Tiran, Valerie Marone, David Messesrsmith, Kevin Cottrell, Jon H. Come, Gabriel Martinez Botella
  • C-MET PROTEIN KINASE INHIBITORS
    Publication number: 20110059936
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 10, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, JR., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • c-MET protein kinase inhibitors
    Patent number: 7872031
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: January 18, 2011
    Assignee: Vertex Pharmaceuticals incorporated
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, Jr., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • INHIBITORS OF C-MET AND USES THEREOF
    Publication number: 20100190774
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Application
    Filed: April 8, 2010
    Publication date: July 29, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: David J. Lauffer, Alexander Aronov, Pan Li, David D. Deininger, Kira McGinty, Dean Stamos, Jon H. Come, Michelle Stewart
  • HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF
    Publication number: 20100144739
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Application
    Filed: September 18, 2007
    Publication date: June 10, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Alexander Aronov, Jon Come, John Court, David Deininger, David Lauffer, Pan Li, Kira McGinty, Suganthini Nanthakumar, Dean Stamos, Kirk Tanner
  • Inhibitors of c-Met and uses thereof
    Patent number: 7728017
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: June 1, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Alexander Aronov, Pan Li, David D. Deininger, Kira McGinty, Dean Stamos, Jon H. Come, Michelle Stewart
  • Selective inhibitors of ERK protein kinase and uses thereof
    Patent number: 7501415
    Abstract: Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: March 10, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Aronov, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 7345054
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: March 18, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov